Mechanism of Action
How sTMS Interrupts Migraine
-
1
Magnetic Pulse Generated
A single high-intensity magnetic pulse is delivered to the occipital cortex, penetrating painlessly through the skull.
-
2
Cortical Excitability Reduced
sTMS suppresses spontaneous and glutamate-induced neuronal activity in the visual cortex, raising the activation threshold.
-
3
CSD Blocked
Cortical Spreading Depression — the wave of neuronal silence underlying migraine aura — is interrupted in vivo (Andreou et al., Brain 2016).
-
4
Thalamocortical Modulation
Downstream thalamocortical pathways are modulated, explaining efficacy in both migraine with and without aura.
Key Clinical Outcomes
What the Data Shows
Publications Library
Peer-Reviewed Research
ESPOUSE Multicenter Study
Evaluated sTMS for preventive migraine treatment across multiple US centers. Primary endpoint — mean reduction in headache days — met with statistical significance.
All secondary endpoints were also met: reduction in acute medication days, improvement in HIT-6 scores, and total reduction in headache days of any pain intensity. These results directly supported FDA clearance for prophylactic treatment of migraine headache.
Lancet Randomized Double-Blind Trial
Sham-controlled RCT at 18 US centers assessing acute sTMS treatment for migraine with aura. Demonstrated superior pain freedom at 2 and 48 hours.
39% pain-free at 2 hours vs. 22% in sham group. Early treatment significantly increased freedom from pain at 24 and 48 hours. This landmark double-blind study established the foundational evidence for sTMS efficacy.
sTMS for Migraine in Adolescents
Open-label pilot assessing feasibility and tolerability in adolescent patients. Found sTMS to be acceptable and well-tolerated in this age group.
The first study to specifically evaluate sTMS in adolescents, filling an important gap in migraine treatment for younger patients who often have limited pharmaceutical options.
12-Month Prospective Analysis
Long-term observational study of sTMS for difficult-to-treat chronic migraine and high-frequency episodic migraine in a clinical setting.
Findings suggest sTMS is an effective, well-tolerated long-term prevention option for patients with difficult-to-treat CM and HFEM — patient groups for whom existing options are often inadequate.
NHS Real-World Experience
Prospective real-world analysis at Guy's and St. Thomas' NHS Foundation Trust, London. Demonstrated effectiveness in high-frequency/chronic migraine patients.
Concluded sTMS may constitute an effective, well-tolerated preventive option and could be included before Botox in treatment pathways — at lower cost to the NHS.
UK Post-Market Pilot Program
Evaluated sTMS for acute treatment across both migraine with and without aura over 12 weeks. Significant pain relief and reduced monthly headache days reported.
One of the first large-scale real-world assessments of sTMS in routine clinical practice, demonstrating that RCT results translate to a broad population including chronic migraine sufferers.
CSD Suppression in Preclinical Models
Demonstrated that sTMS blocks Cortical Spreading Depression in vivo and modulates thalamocortical pathways, explaining broad efficacy.
This Oxford/UCSF collaborative study used preclinical migraine models to establish the neurobiological basis for sTMS, showing CSD blockade and a novel thalamocortical modulatory capacity.
Cortical Neuronal Firing Suppression
Showed sTMS below the motor threshold suppresses spontaneous and glutamate-induced visual cortex activity, raising CSD induction threshold.
These IHC 2017 findings directly link the cortical mechanism to clinical effect, explaining why sTMS benefits patients even when applied preventively and not just acutely.
Comprehensive TMS Safety Review
Systematic review of safety data from single-pulse and repetitive TMS studies. Concluded sTMS has strong biological, empirical, and clinical trial safety support.
Specifically addresses sTMS in its role as a migraine treatment, making it the definitive safety reference for clinicians considering prescribing sTMS to their patients.
sTMS During Pregnancy
Abstract demonstrating sTMS as a non-drug treatment option for pregnant migraine patients, with no contraindications identified for use during pregnancy or breastfeeding.
Supported by JAMA data showing MRI exposure in the first trimester is not associated with increased risk of harm to the fetus — demonstrating the biological safety of non-ionizing electromagnetic exposure.
AHS Consensus Statement 2021
American Headache Society update on integrating new migraine treatments, including sTMS, into evidence-based clinical practice.
Provides practical guidance for neurologists on treatment positioning of sTMS alongside newer pharmacological options including CGRP-targeting agents.
NHS Cost-Effectiveness Analysis
Evaluated the UK NHS cost impact of sTMS for chronic migraine versus Botox, finding substantial cost-reduction potential under a risk-share model.
Under a risk-share reimbursement model where NHS pays only for responders, sTMS generates meaningful savings vs. conventional Botox for refractory chronic migraine management.
Evidence Timeline
A Decade of Discovery
Lancet RCT Published
Landmark sham-controlled trial at 18 US centers establishes acute sTMS efficacy for migraine with aura.
Pregnancy Safety Data
First abstract reporting sTMS use in pregnant migraine patients with favorable tolerability profile.
UK Post-Market RWE
Real-world UK pilot data confirms both acute and preventive benefit in episodic and chronic migraine.
Mechanism Elucidated
Andreou et al. (Brain) confirm CSD blockade and thalamocortical modulation as dual mechanisms of action.
FDA Prophylactic Clearance
ESPOUSE trial results support FDA clearance for preventive treatment — a milestone for drug-free migraine prevention.
Long-Term Durability Confirmed
12-month NHS analysis and AHS consensus statement affirm sTMS as an established, guideline-supported option.
Safety Profile
Designed for Tolerability
Drug-Free
No systemic drug exposure; eliminates medication side-effect concerns and overuse risk.
Pregnancy Safe
No contraindications identified for pregnant or breastfeeding patients. Consult your HCP.
Adolescent Tolerated
Well-accepted in open-label adolescent pilot; no serious adverse events reported.
Non-Ionizing
Magnetic pulse carries no radiation; safety profile supported across TMS literature since the 1980s.
Home Use
Portable device designed for self-administration; removes barriers of clinic-based neuromodulation.
Clinically Reviewed
Comprehensive safety review published in Headache (2010) covering both sTMS and rTMS modalities.
Two Distinct FDA Clearances for Migraine
sTMS is FDA-cleared for the acute treatment of migraine with aura and for the prophylactic (preventive) treatment of migraine headache — one of the only devices to hold both designations.